Search

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Prescription Digital Therapeutics a New Frontier in Mental Health Care

Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.

New analysis supports long-term treatment with Ofev® in SSc-ILD patients

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.

OFEV® (nintedanib) Data in Patients with ILDs | Boehringer Ingelheim US

Studies from American Thoracic Society Congress show the proportion of patients with 10% or greater declines in lung function were lower in the OFEV group.

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)

J-Code Issued for SPEVIGO

Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Larry's Story: The Power of Patient Advocacy

For Larry, patient advocacy is an important part of his cancer journey. Learn more about Larry and his role with GO2 for Lung Cancer.

Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors

Duluth, Georgia

Boehringer Ingelheim Animal Health employs about

Could decentralised trials transform the way we view depression?

Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.

Discover your hidden talent with BI Open – the new platform for data science enthusiasts

Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.

Women Inspiring Women: 5 questions for 6 women

PI Update for Pradaxa® (dabigatran etexilate) | BI US

Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.

Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US

BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) analysis reinforces established safety profile

Boehringer Ingelheim Venture Fund

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Our Partners: University of Georgia USA

Coliform Mastitis: the facts to know | Boehringer Ingelheim US

Click here to learn more about different management practices that can help you to improve your dairy herd's bottom line and productivity.

Pharmacy Rotations

Click here to read testimonies from our employees who enrolled in our pharmacy rotations academic program.

Clinical Pharmacology

Boehringer Ingelheim is proud to offer a new two-year fellowship within Clinical Pharmacology. Click here to find out more.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers